NICE proposes to withdraw Alzheimer's drugs from NHS.
作者信息
Kmietowicz Zosia
出版信息
BMJ. 2005 Mar 5;330(7490):495. doi: 10.1136/bmj.330.7490.495-a.
Abstract
摘要
相似文献
1
NICE proposes to withdraw Alzheimer's drugs from NHS.英国国家卫生与临床优化研究所提议从英国国家医疗服务体系中撤下治疗阿尔茨海默病的药物。
BMJ. 2005 Mar 5;330(7490):495. doi: 10.1136/bmj.330.7490.495-a.
2
Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.欧盟抗痴呆药物处方和报销标准中令人担忧的随意性。
Int J Geriatr Psychiatry. 2006 Jan;21(1):29-31. doi: 10.1002/gps.1493.
3
New drugs for Alzheimer's disease in Japan.日本治疗阿尔茨海默病的新药
Psychiatry Clin Neurosci. 2011 Aug;65(5):399-404. doi: 10.1111/j.1440-1819.2011.02253.x.
4
Anti-Alzheimer drugs: life-threatening adverse effects.抗阿尔茨海默病药物：危及生命的不良反应。
Prescrire Int. 2007 Feb;16(87):16.
5
Alzheimer's disease: beware of interactions with cholinesterase inhibitors.阿尔茨海默病：谨防与胆碱酯酶抑制剂的相互作用。
Prescrire Int. 2006 Jun;15(83):103-6.
6
UK government guidance on Alzheimer's drugs postponed.英国政府关于治疗阿尔茨海默病药物的指导意见被推迟。
Drug Discov Today. 2005 Sep 1;10(17):1132. doi: 10.1016/S1359-6446(05)03586-5.
7
International price comparisons of Alzheimer's drugs: a way to close the affordability gap.国际间阿尔茨海默病药物价格比较：缩小可负担性差距的一种途径。
Int Psychogeriatr. 2009 Dec;21(6):1116-26. doi: 10.1017/S104161020999086X. Epub 2009 Sep 8.
8
How do we treat people with dementia in Croatia.我们在克罗地亚如何治疗痴呆症患者。
Psychiatr Danub. 2010 Jun;22(2):363-6.
9
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.阿尔茨海默病行为症状的治疗策略：聚焦早期药物干预
Pharmacotherapy. 2007 Mar;27(3):399-411. doi: 10.1592/phco.27.3.399.
10
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.中重度阿尔茨海默病患者从多奈哌齐转换为美金刚治疗的耐受性
Int J Geriatr Psychiatry. 2008 Sep;23(9):979-81. doi: 10.1002/gps.1979.
引用本文的文献
1
Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.胆碱酯酶抑制剂治疗阿尔茨海默病的停药、疗效和安全性：43 项纳入 16106 例患者的随机临床试验的荟萃分析和荟萃回归。
Int J Neuropsychopharmacol. 2017 Jul 1;20(7):519-528. doi: 10.1093/ijnp/pyx012.
2
Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial.阿尔茨海默病药物的用药依从性和耐受性：一项随机对照试验的研究方案。
Trials. 2013 May 4;14:125. doi: 10.1186/1745-6215-14-125.
3
The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.亲脂性“子弹”命中靶点：金刚烷衍生物的药物化学
Chem Rev. 2013 May 8;113(5):3516-604. doi: 10.1021/cr100264t. Epub 2013 Feb 25.
4
NMDA receptors in clinical neurology: excitatory times ahead.临床神经学中的NMDA受体：兴奋的未来
Lancet Neurol. 2008 Aug;7(8):742-55. doi: 10.1016/S1474-4422(08)70165-0.
5
Treatment of Alzheimer's disease across the spectrum of severity.阿尔茨海默病全病程的治疗
Clin Interv Aging. 2006;1(2):131-42. doi: 10.2147/ciia.2006.1.2.131.
6
Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.多奈哌齐治疗阿尔茨海默病的长期成本效益
Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):330-6. doi: 10.1007/s00406-007-0727-1. Epub 2007 Apr 1.
7
Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping.多奈哌齐主要减轻东莨菪碱引起的精神运动功能缺陷，对简单条件反射和注意力有中等程度影响，对工作记忆和空间定位有轻微影响。
Psychopharmacology (Berl). 2006 Nov;188(4):629-40. doi: 10.1007/s00213-006-0556-3. Epub 2006 Sep 27.
8
Cholinesterase inhibitors: drugs looking for a disease?胆碱酯酶抑制剂：在寻找疾病的药物？
PLoS Med. 2006 Apr;3(4):e140. doi: 10.1371/journal.pmed.0030140. Epub 2006 Apr 11.
Zotero 插件